Article

Pros of early diagnosis outweigh cons

San Francisco - Early diagnosis of glaucoma does matter because it offers an opportunity to alter the significant morbidity associated with this disease, said Kuldev Singh, MD, MPH, professor of ophthalmology, director, glaucoma service, Stanford University, Stanford, CA.

San Francisco - Early diagnosis of glaucoma does matter because it offers an opportunity to alter the significant morbidity associated with this disease, said Kuldev Singh, MD, MPH, professor of ophthalmology, director, glaucoma service, Stanford University, Stanford, CA.

“With early diagnosis there is an opportunity for earlier treatment that can improve the odds of preventing functional vision loss. However, even if intervention is not chosen, early diagnosis still offers greater opportunities for increasing patient awareness about the disease continuum and need for follow-up as well as to assess disease velocity that can be important in guiding treatment decisions that will help prevent vision loss,” Dr. Singh said.

Early diagnosis is accompanied by potential pitfalls that need to be considered. One of those problems is creation of patient anxiety, and to address that clinicians need to assure patients that their risk of going blind is low if they adhere to regular follow-up and prescribed therapy.

In addition, there is a potential for exposing patients to unnecessary treatment and, even more commonly, overtreatment.

“To avoid inappropriately aggressive treatment, management decisions need to be based on the lifetime risk of functional vision loss and weighed against the benefits of therapy. With that approach, early diagnosis is beneficial for glaucoma patients,” Dr. Singh said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.